Axsome Therapeutics (AXSM) Assets Average (2016 - 2026)

Axsome Therapeutics has reported Assets Average for 11 years, with the latest figure at $701.7 million in Q1 2026.

• Quarterly Assets Average rose 20.45% year-over-year to $701.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $701.7 million (up 20.45% YoY) and the FY2025 annual result came in at $629.2 million, up 8.78% from the prior year.
• Assets Average climbed to $701.7 million in Q1 2026 per AXSM's latest filing, from $679.5 million in the prior quarter.
• Over five years, Assets Average peaked at $701.7 million in Q1 2026 and troughed at $88.2 million in Q1 2022.
• A 5-year average of $491.2 million and a median of $565.0 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2023: Assets Average slumped 50.05% in 2022, then soared 308.66% in 2023.
• Over 5 years, Assets Average stood at $335.2 million in 2022, then jumped by 77.36% to $594.5 million in 2023, then retreated by 4.97% to $565.0 million in 2024, then grew by 20.28% to $679.5 million in 2025, then advanced by 3.26% to $701.7 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $701.7 million, $679.5 million, and $654.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.